EGFR and non-small cell lung carcinoma: And recently, we also reported that proton pump inhibitor, lansoprazole, in combination with gefitinib showed synergistic antitumor effect on NSCLC A549 cells and mouse xenograft models with wild-type EGFR (Zhao et al., 2021).